美股市场个股详情

LLY 礼来

添加自选
  • 751.640
  • -7.950-1.05%
收盘价 04/12 16:00 (美东)
  • 750.040
  • -1.600-0.21%
盘后 19:59 (美东)
7146.34亿总市值129.59市盈率TTM
全部分时
  • 5日
  • 日K
  • 周K
  • 月K
  • 季K
  • 年K

资金分布

单位: --

资金流向

实时

暂无数据

评论

    $500 Challenge Trade Update

    BOT +1 VERTICAL LLY 100 (Weeklys) 12 APR 24 782.5/785 CALL @.26 LMT Net Debit [TO OPEN] This trade has filled. This is a $500 CHALLENGE Trade. LLY has dropped down quite a bit today but the BBs are still holding up well and we are at support of our consolidated range with the Bull DB still valid into tomorrow. I added 1 more contract which increases the risk slightly but reduces the net average. If CPI pops back up tomorrow I will look to close this out ideally for a w...

    $500 CHALLENGE TRADE

    BOT +1 VERTICAL LLY 100 (Weeklys) 12 APR 24 782.5/785 CALL @1.02 LMT Net Debit [TO OPEN] This trade has filled. This is a $500 CHALLENGE Trade. LLY has had a nice pullback into the 10 and 30 SMA in an overall Bullish Trend with recent True Low and Dark Pool Levels. LLY still has a valid Bull DB, so at the very least looking for this to test 786 within the next couple days if not move higher for a quick win. Do what you think is best for your account. Keep in mind your capital...
    Top companies and drugs by sales in 2023 from Nature Reviews Drug Discovery.
    $礼来(LLY.US)$ and  $诺和诺德(NVO.US)$ are not on the list (they will be next year of course...). Just shows how forward looking our industry is as both have higher market caps than any of the top 10 companies 
    图片
    $礼来(LLY.US)$ 哈哈哈,礼来崩溃了
    $诺和诺德(NVO.US)$ & $礼来(LLY.US)$ 's MCap increased by $285 bil in Q1 2024 alone, driven mostly by growth of the GLP-1 franchises,
    Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
    But let's put that $285 bil incr in mkt value into perspective,
    $艾伯维公司(ABBV.US)$ has a $315 bil MCap, not much bigger than the  combined Q1 incr in mkt value for LLY & NVO,
    ABBV had $54 bil in revenue in 2023, compared ...
    图片
阅读更多

分析

分析师评级

暂无数据

目标价预测

暂无数据

热议
美股
综合热度
股票代码
最新价
涨跌幅